Kirsch Andrijana, Gindlhuber Juergen, Zabini Diana, Osto Elena
Division of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.
Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Front Cardiovasc Med. 2025 Jan 6;11:1510148. doi: 10.3389/fcvm.2024.1510148. eCollection 2024.
Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies.
肥胖是21世纪全球主要的健康问题之一，与许多合并症相关，如2型糖尿病（T2DM）、代谢功能障碍相关脂肪性肝病以及早期侵袭性动脉粥样硬化性心血管疾病，后者是全球主要的死亡原因。胆汁酸（BAs）和肠促胰岛素是分别参与脂肪酸消化吸收和胰岛素分泌的肠道激素。近年来，BAs和肠促胰岛素越来越被认为是关键信号分子，其作用靶点不仅限于胃肠系统，还涉及多个组织和器官。此外，基于肠促胰岛素的疗法彻底改变了T2DM和肥胖症的治疗。本综述重点介绍了目前关于肥胖中BA稳态失调的知识，特别关注动脉粥样硬化以及肠促胰岛素的动脉粥样硬化调节作用和目前可用的基于肠促胰岛素的疗法。
